{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:51:03Z","timestamp":1778673063306,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jchromb.2021.122905","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T19:11:08Z","timestamp":1629573068000},"page":"122905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography\/tandem mass spectrometry"],"prefix":"10.1016","volume":"1181","author":[{"given":"Zi-Xuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jchromb.2021.122905_b0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jchromb.2021.122905_b0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jchromb.2021.122905_b0015","first-page":"4","article-title":"Discovery, Development, and clinical applications of bortezomib","volume":"18","author":"Jung","year":"2004","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.jchromb.2021.122905_b0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jchromb.2021.122905_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jchromb.2021.122905_b0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jchromb.2021.122905_b0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jchromb.2021.122905_b0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jchromb.2021.122905_b0045","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jchromb.2021.122905_b0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/tx050313d","article-title":"Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction","volume":"19","author":"Labutti","year":"2006","journal-title":"Chem. Res. Toxicol."},{"issue":"6","key":"10.1016\/j.jchromb.2021.122905_b0055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","article-title":"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites","volume":"33","author":"Pekol","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2021.122905_b0060","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2021.122905_b0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","article-title":"Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry","volume":"903","author":"Kralj","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2021.122905_b0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2021.122905_b0075","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1353\/dem.2007.0038","article-title":"What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research","volume":"44","author":"McDade","year":"2007","journal-title":"Demography"},{"key":"10.1016\/j.jchromb.2021.122905_b0080","doi-asserted-by":"crossref","first-page":"1631S","DOI":"10.1093\/jn\/131.5.1631S","article-title":"Use of filter paper for the collection and analysis of human whole blood specimens","volume":"131","author":"Mei","year":"2001","journal-title":"J. Nutr."},{"key":"10.1016\/j.jchromb.2021.122905_b0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/FTD.0b013e31818d9fdb","article-title":"Determination of morphine and 6-acetylmorphine in blood with use of dried blood spots","volume":"30","author":"Garcia Boy","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2021.122905_b0090","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1111\/j.1528-1167.2009.02204.x","article-title":"A new rapid micromethod for the assay of phenobarbital from dried blood spots by LC-tandem mass spectrometry","volume":"50","author":"la Marca","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jchromb.2021.122905_b0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mas.21441","article-title":"The use of mass spectrometry to analyze dried blood spots","volume":"35","author":"Wagner","year":"2016","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jchromb.2021.122905_b0100","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"Pt 2","key":"10.1016\/j.jchromb.2021.122905_b0105","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.clinthera.2009.11.012","article-title":"Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study","volume":"31","author":"Venkatakrishnan","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jchromb.2021.122905_b0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2021.122905_b0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2016.06.009","article-title":"LC-MS\/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients","volume":"1028","author":"Shu","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2021.122905_b0120","first-page":"140","article-title":"Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation","volume":"21","author":"Cheung","year":"2008","journal-title":"Transpl. Int."},{"key":"10.1016\/j.jchromb.2021.122905_b0125","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jpba.2006.11.023","article-title":"Therapeutic drug monitoring of tacrolimus with the dried blood spot method","volume":"44","author":"Hoogtanders","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2021.122905_b0130","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/rcm.2158","article-title":"Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography\/tandem mass spectrometry","volume":"19","author":"Koal","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2021.122905_b0135","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpba.2008.11.021","article-title":"Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry","volume":"50","author":"van der Heijden","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2021.122905_b0140","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clinbiochem.2010.06.014","article-title":"The analysis of dried blood spot samples using liquid chromatography tandem mass spectrometry","volume":"44","author":"Keevil","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jchromb.2021.122905_b0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2021.122905_b0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40262-019-00803-y","article-title":"A Semi-Mechanistic Population Pharmacokinetic\/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"59","author":"Janssen","year":"2020","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322100386X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322100386X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:05:39Z","timestamp":1761606339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157002322100386X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"alternative-id":["S157002322100386X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122905","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography\/tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122905"}}